HKMPY.US Hikma Pharmaceuticals PLC ADR

Healthcare Pharmaceuticals USA Stocks
47.75 USD
Close of Nov 15, 2026
30.46 47.75
Market cap
USD 4.94B
P/E
13.6x
P/B
1.96x
ROE
35.3%
Dividend yield
3.75%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is HKMPY.US undervalued?

Graham number
Price47.75
Graham value43.94
Premium8.7%

HKMPY.US trades 8.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hikma Pharmaceuticals PLC ADR fundamental analysis

No fundamental analysis for Hikma Pharmaceuticals PLC ADR yet.

Hikma Pharmaceuticals PLC ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hikma Pharmaceuticals PLC ADR

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and ot…

Full company profile